Mark Frasier, PhD

Job title:

Associate Director, Research Programs

Organization:

The Michael J. Fox Foundation for Parkinson's Research (MJFF)

Technology:

biomarkers

PD Guide Terms:

Etiology

Clinical & Biological Features

Therapeutic Development

Contributions:

Published Contributions:

Validating PD targets: FK506 binding proteins

response to: POWs: Papers of the Week

22 Feb 2010 06:34 PM EST

Digging through the POWs, I found this interesting paper from Veerle Baekelandt's group describing the role of FK506 binding proteins (FKBPs) in alpha-synuclein accumulation and alpha-synuclein ...

Responses: 1

MJFF LRRK2 antibody update

response to: LRRK2 Summit

10 Feb 2010 07:27 PM EST

As mentioned at the LRRK2 summit, MJFF is working with multiple vendors to generate quality LRRK2 antibodies. Currently there are several promising antibodies that we have ordered to be batch ...

Alpha-synuclein Summit: MJFF Summary and Outcomes Report

response to: Alpha-synuclein Summit

8 Feb 2010 11:30 AM EST

MJFF recently hosted a Summit to discuss the translation of alpha-synuclein discoveries into meaningful therapies for patients. Below are some takeaways from the discussion. ...

Workgroups:

Placebo Response Workshop